Delivering tomorrow's genetic medicines, today™
Vancouver, British Columbia
NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies develop genetic medicines for previously untreatable diseases. NVTx is delivering tomorrow's genetic medicines, today. For more information, please visit nanovationtx.com.
On-site · Vancouver
The Scientist III will design and execute preclinical in vivo and in vitro research to advance pharmaceutical formulation performance. They will also mentor team members, manage project plans, and contribute to patent applications and scientific literature reviews.